President Trump is expected to tap former FDA and CMS official Scott Gottlieb to run FDA, an agency that the president recently criticized for impeding innovative new medical products. Gottlieb is likely to favor reducing regulatory burdens for companies. But industry hopes one of his first priorities will be to help push a user-fee reauthorization agreement that was negotiated with the Obama administration through Congress.
The choice comes after months of uncertainty and signs that the president was flirting with making a pick for the commissioner post that would more sharply upend the regulatory system...